Last Update: 2023-10-04 11:37:21
Brickell Biotech Inc. ( BBI ) https://www.brickellbio.com
Biotechnology & Medical Research
United States
Historical Returns*:
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Other Earnings and Cash Flow Stats:
Brickell Biotech Inc. ( BBI ) Net Income TTM ($MM) is -20.86
Brickell Biotech Inc. ( BBI ) Operating Income TTM ($MM) is -20.97
Brickell Biotech Inc. ( BBI ) Owners' Earnings Annual ($MM) is -21.88
Brickell Biotech Inc. ( BBI ) Current Price to Owners' Earnings ratio is -0.19
Brickell Biotech Inc. ( BBI ) EBITDA TTM ($MM) is -20.95
Brickell Biotech Inc. ( BBI ) EBITDA Margin is -861.82%
Capital Allocation:
Brickell Biotech Inc. ( BBI ) has paid 0.00 dividends per share and bought back -2.893291 million shares in the past 12 months
Brickell Biotech Inc. ( BBI ) has increased its debt by 0.073 million USD in the last 12 months
Capital Structure:
Brickell Biotech Inc. ( BBI ) Interest-bearing Debt ($MM) as of last quarter is 0
Brickell Biotech Inc. ( BBI ) Annual Working Capital Investments ($MM) are 1
Brickell Biotech Inc. ( BBI ) Book Value ($MM) as of last quarter is 15
Brickell Biotech Inc. ( BBI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Brickell Biotech Inc. ( BBI ) has 10 million in cash on hand as of last quarter
Brickell Biotech Inc. ( BBI ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Brickell Biotech Inc. ( BBI ) has 5 common shares outstanding as of last quarter
Brickell Biotech Inc. ( BBI ) has 0 million USD of preferred stock value
Academic Scores:
Brickell Biotech Inc. ( BBI ) Altman Z-Score is 0.00 as of last quarter
Brickell Biotech Inc. ( BBI ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Brickell Biotech Inc. ( BBI ) largest shareholder is Ronald Blue Trust, Inc. owning 916 shares at 0.00 ($MM) value
HARDY REGINALD L(CHAIRMAN OF THE BOARD) Executed Type F Transaction for -15180 shares of Brickell Biotech Inc. ( BBI ) for the amount of $3474.70 on 2021-12-31
1.21% of Brickell Biotech Inc. ( BBI ) is held by insiders, and 13.08% is held by institutions
Brickell Biotech Inc. ( BBI ) went public on 1993-03-15
Other Brickell Biotech Inc. ( BBI ) financial metrics:
Unlevered Free Cash Flow:-20.71
Operating Margin:-48233.33
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-173.36
Buffet's Owners Earnings:-21.88
Price to Owner's Earnings:-0.19
About Brickell Biotech Inc. ( BBI ) :
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various preion therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
User Content from Tickernomics. Created by Luminus.

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.